What does PD-L1 expression mean for my Triple-Negative Breast Cancer treatment options

Understanding PD-L1 Expression in Triple-Negative Breast Cancer

I'm glad you're asking about this—PD-L1 expression is an important biomarker that directly influences your treatment options for triple-negative breast cancer (TNBC).

What PD-L1 Expression Means

PD-L1 (programmed death-ligand 1) is a protein that cancer cells can produce to "hide" from your immune system. Think of it like a cloak: when cancer cells express PD-L1, they suppress your body's T cells (immune cells that normally attack cancer), preventing them from recognizing and destroying the cancer.

When your pathology report shows PD-L1 positive, it means your cancer cells are expressing this protein. This is actually good news because it opens up a specific treatment pathway that many TNBC patients benefit from.

How PD-L1 Status Affects Your Treatment Options

According to NCCN Guidelines for Invasive Breast Cancer, your PD-L1 status determines which first-line treatments your oncologist will consider:

If You Have PD-L1 CPS ≥10 (PD-L1 Positive):

Preferred first-line option: Pembrolizumab (Keytruda) + chemotherapy

This combination works by:

• Pembrolizumab blocks PD-L1, essentially removing the "cloak" so your immune system can see and attack the cancer
• Chemotherapy (albumin-bound paclitaxel, paclitaxel, or gemcitabine with carboplatin) directly kills cancer cells
• Together, they create a powerful one-two punch: chemotherapy damages cancer cells while immunotherapy helps your immune system recognize them

This is a Category 1 recommendation (the highest level of evidence), meaning strong clinical data supports this approach.

If You Have PD-L1 CPS <10 (PD-L1 Negative) AND No BRCA Mutation:

Standard chemotherapy alone is typically recommended, as the immunotherapy benefit is less clear without higher PD-L1 expression.

If You Have PD-L1 CPS <10 BUT Have a Germline BRCA1/2 Mutation:

You have additional options:

• PARP inhibitors (olaparib or talazoparib) - these target the BRCA mutation
• Platinum-based chemotherapy (cisplatin or carboplatin)

Important Context About PD-L1 Testing

According to the NCCN Guidelines, here's what you should know:

• PD-L1 is measured using a specific test (22C3 antibody) with a scoring system called "Combined Positive Score" (CPS)
• The cutoff matters: A CPS of 10 or higher is considered positive for TNBC treatment decisions
• PD-L1 expression is dynamic, meaning it can change over time or with treatment
• It's not a perfect biomarker, but it's currently the best available tool we have to predict who will respond to checkpoint inhibitor immunotherapy

Questions to Ask Your Oncologist

Since PD-L1 status is so important for your treatment plan, here are specific questions to discuss:

1. "What is my PD-L1 CPS score, and what does that mean for my specific treatment options?"

2. "Based on my PD-L1 status, do you recommend pembrolizumab with chemotherapy, or would you recommend a different approach? Why?"

3. "Have I been tested for germline BRCA1/2 mutations? If not, should I be?" (This affects whether PARP inhibitors are an option)

4. "What are the specific chemotherapy drugs you're recommending to pair with pembrolizumab, and why that combination?"

5. "What side effects should I expect from the combination of immunotherapy and chemotherapy, and how will we monitor for them?"

6. "If my cancer progresses on this first-line treatment, what are the second-line options?"

The Bottom Line

If your PD-L1 is positive (CPS ≥10), you have access to an FDA-approved immunotherapy combination that has shown strong clinical benefit for TNBC patients. This represents a significant advancement in TNBC treatment, as triple-negative cancers historically had fewer targeted options than hormone-receptor-positive or HER2-positive breast cancers.

Your oncologist will integrate your PD-L1 status with other factors (your overall health, other biomarkers, stage of disease) to create your personalized treatment plan.

---

Sources:

• NCCN Guidelines for Invasive Breast Cancer (Version 5.2025) - Systemic Therapy for Recurrent Unresectable or Stage IV Disease
• NCCN Guidelines for Patients: Metastatic Breast Cancer - PD-L1 Testing and Treatment Options

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.